Menu
ncarol.com
  • Home
  • Business
  • Health
  • Real Estate
  • Arts
  • Non-profit
  • Technology
  • Education
  • Books
ncarol.com

OncoBeta GmbH and Australian Nuclear Science and Technology Organisation sign Letter of Intent to establish manufacturing site in Australia
ncarol.com/10075130

Trending...
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
Rhenium Sct Produced In Australia Capture Obg Press Photo 1 No Language 002 OncoBeta GmbH
Innovative medical device Rhenium-SCT® therapy for non-melanoma skin cancer to be produced in Australia

MUNICH - ncarol.com -- Garching n. Munich, Germany and Lucas Heights, NSW, Australia – OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies for non-melanoma skin cancers and the Australian Nuclear Science and Technology Organisation (ANSTO), are pleased to announce that they have signed a Letter of Intent to establish manufacturing and distribution in Australia for OncoBeta's novel Rhenium-SCT® therapeutic.

ANSTO is the leader in nuclear science in Australia and has extensive experience in the manufacturing of radiopharmaceutical diagnostics, therapies and medical devices, they are the perfect partner for OncoBeta to work with to introduce the Rhenium-SCT® product to Australia. Together, the parties will achieve a key milestone, bringing the production of Rhenium-SCT® closer to Australians suffering of non-melanoma skin cancer. OncoBeta is currently in the process of securing Australian Market Approval for its product.

The global incidence of non-melanoma skin cancers has been drastically increasing over the past decades. It is estimated that there are over 5 million non-melanoma skin cancer cases reported globally each year. Non-melanoma skin cancer is the most common type of cancer in Australia with over 500,000 people each year being diagnosed with one or more of these cancers.

ANSTO General Manager Business Development and Commercialization, Rosanne Robinson stated, "ANSTO is proud to partner with OncoBeta to establish local manufacturing of Rhenium-SCT® and to continue delivering on our core mission of improving the health of Australians and supporting industry. ANSTO has a long-standing relationship with OncoBeta and look foward Australian patients having access to their innovative therapy for non-melanoma skin cancers. OncoBeta will join our growing nandin innovation community, focussed on attracting entrepreneurs, early stage start-ups and innovative companies who want to leverage the opportunity to be co-located with ANSTO and to access our unique expertise in the nuclear industry."

More on ncarol.com
  • Lamaze International and Plumtree Baby Launch New Childbirth Education Materials
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Walnut Hills Launches Off-Grid Hempcrete Homes and Eco-Retreat in Western NC
  • The AML Shop Launches New Financial Investigations Unit, Appoints Director to Lead the Initiative

Nicholas H. Vetter, Chief Operating Officer of OncoBeta® GmbH stated: "We are incredibly excited to start extending our production footprint to Australia. It's a great pleasure to work towards solidifying a partnership with ANSTO so we can do our jobs: to bring the Rhenium-SCT® to large patient populations suffering of non-melanoma skin cancer. With this partnership we can finally move beyond trying to service the market from our other production sites in Europe or South Africa. It's a perfect time to expand our business."

About the Rhenium-SCT® (Skin Cancer Therapy)

The Rhenium-SCT® is a non-invasive, painless therapy generally providing for unparalleled aesthetic results, even in cases otherwise considered difficult to treat. The Rhenium-SCT® utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properties for the treatment of NMSCs (non-melanoma skin cancers). Due to the specially designed devices and accessories the Rhenium-SCT® compound never comes in direct contact with the patients' skin and the application is safe and simple for the applying physician. Most cases of non-melanoma skin cancers (Basal Cell Carcinomas and Squamous Cell Carcinomas) can be treated using the Rhenium-SCT® with a single application, applied in one single session. Scar-free healing of the treated lesion area and the regeneration of healthy tissue occurs usually within a few weeks after treatment.

About ANSTO

ANSTO leverages great science to deliver big outcomes. We partner with a broad range of industry partners to apply new technologies to provide real-world benefits. Our work improves human health, saves lives, builds our industries and protects the environment.  ANSTO is the home of Australia's most significant landmark and national infrastructure for research. Thousands of scientists from industry and academia benefit from gaining access to state-of-the-art instruments every year.

More on ncarol.com
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • The Herbal Care, Led by Markel Bababekov, Becomes a Top Dispensary in NYC's Upper East Side
  • Digital Watchdog Launches New myDW Cloud Services
  • Stan Fitzgerald Appointed Acting Press Secretary for Veterans for America First VFAF Georgia State Chapter

For more information visit www.ansto.gov.au

About OncoBeta® GmbH

OncoBeta® GmbH with its headquarters located at the Garching Technology and Founders Center GATE near Munich, is a privately held medical device company, specializing in the development and commercialization of state-of-the-art, innovative therapies utilizing epidermal radioisotope applications. Since its foundation, OncoBeta® GmbH has concentrated its efforts on the development, regulatory approval(s) and commercialization of the epidermal radioisotope therapy Rhenium-SCT® (Skin Cancer Therapy), targeting non-melanoma skin cancers. Since then, OncoBeta® has successfully perfected the customized application and device management system in conformity with all health, safety, and environmental protection regulatory standards.

Find out more about the Rhenium-SCT® at www.oncobeta.com

Follow us on social media:

LinkedIn: https://www.linkedin.com/company/oncobeta-gmbh/

Facebook: https://www.facebook.com/oncobeta/

Forward-looking statements

This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OncoBeta's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OncoBeta's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OncoBeta® undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Contact
OncoBeta GmbH
info@oncobeta.com
+49 (89) 5484224 0


Source: OncoBeta GmbH
Filed Under: Health

Show All News | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Community-Based Marriage Enrichment Support
  • Michael Reafsnyder opens solo exhibition at Scott Richards Contemporary Art in San Francisco
  • Valley Sleep Therapy Expands to Prescott with New Location at Crossings Road
  • $17.4 Million Total Revenue for First Half of 2025 (up 31.8% YOY) for Global Wet Trades Services Provider with High Value Bitcoin Investments
  • $12.8 Million Net Revenue for 2024 for Cloud-Based Crowdsourcing Recruitment and SaaS-Enabled HR Solutions Provider: Baiya International Group Inc
  • Scott Burton Releases Chaos: The Weight of a Memory, a Poetic Journey Through What Still Lingers
  • The Business Hyve Opens Waitlist for Groundbreaking Community Built for Small Business Success
  • Hire Virtue Announces Executive Sponsorship Opportunity for Houston Hiring Blitz & Job Fair on August 6, 2025
  • Inked & Maxim Model Teisha Mechetti Turns Heads—And Builds Community Impact
  • Plan to Launch Silo Technologies' Cybersecurity Pilot Program for Ultimate Nationwide Deployment via Exclusive Partnership: Stock Symbol: BULT
  • Robert Michael & Co. Real Estate Team Celebrates Industry Recognition and Showcases Premier Central Florida Listings
  • AI-Based Neurotoxin Countermeasure Initiative Launched to Address Emerging National Security Needs: Renovaro, Inc. (N A S D A Q: RENB)
  • The Naturist World Just Shifted — NaturismRE Ignites a Global Resurgence
  • $796,000 in Q2 Revenue Marks Highest Earnings to Date on 3 Trailing Quarters of Profitability in Multi-Billion Homebuilding Sector: Stock Symbol: IVDN
  • Cybersecurity is THE Hot Market Sector; Revenues, Earnings & Profit matter; Only 33 Million Shares + a Huge Short Position Equal an Undervalued Stock
  • Despite Global Calls for a Ban, US Child Psychiatry Pushes Electroshock for Kids
  • Franco Polished Plaster Celebrates 35 Years of Bringing Walls to Life in the UK
  • Spartan & Guardians Partner with Guitar Legend Buckethead to Support Global Child Rescue Efforts
  • Preliminary.online Introduces Short-Term Job-Readiness Courses with Employer-Verified Certifications
  • Psychologist-Turned-Hermeticist Releases Modern Guide to the Seven Hermetic Principles
_catLbl0 _catLbl1

Popular on ncarol.com

  • Real Estate CEO Launches Explosive New Book After $275,784 Wire Fraud Incident - 108
  • Experience Trembling Firsthand with the New AgeMan® Tremor Simulator - 106
  • Kaplan Morrell Applauds Passage of Landmark Workers' Compensation Reform in Colorado
  • JMC Princess Announces Release of Empowering New Single "PRETTY" – A Summer Anthem for Young Girls Everywhere
  • RemoteSEO Launches Targeted Digital Marketing for RTP Businesses
  • Let's Talk Series: At the Crossroads: Immigration Today
  • csky.ai & DuoKey Launch Secure AI Transcription Solution for Microsoft 365
  • Mauro Schnaidman named as Managing Director in Miami, Florida
  • Continued Streak of Recognitions with Multiple Chambers and Partners Rankings
  • Manhattan Boutique Real Estate Collaborates with InterContinental Hotels NYC in a Branding Partners Personalized Approach

Similar on ncarol.com

  • New Release: 'The Invisible Alternative' Unveiled by Atrisk Corporation, Resilient
  • Why Regular Visits to a Dentist in Kernersville Protect More Than Just Your Smile
  • $18 Price Target Issued in New Research Report After $34 Million Revenue Forecast from Acquisition; $101.5 Million Net Revenue in 2025; NAS DAQ: IQST
  • West Dentistry Welcomes New Oral Surgeon to Enhance Patient Care
  • Raidium révolutionne le diagnostic de la Sclérose en Plaques en partenariat avec l'Hôpital Fondation Adolphe de Rothschild
  • New Podcast "Spreading the Good BUZZ" Hosted by Josh and Heidi Case Launches July 7th with Explosive Global Reach and a Mission to Transform Lives
  • Digital Watchdog Launches New myDW Cloud Services
  • AI Innovation Dual-Strategy Business Model Focused on Real Estate Development for Strategic Expansion: OFA Group, (N A S D A Q: OFAL)
  • Retired Hobbyist Launches Bold Weekly Album Project Using AI Songwriting Tools
  • Eolian Signs New Information Exchange Agreement with the U.S. Department of Defense for Technology Innovation
Copyright © 2025 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute